|
1
|
Gray JM, Rasanayagam S, Engel C and Rizzo
J: State of the evidence 2017: An update on the connection between
breast cancer and the environment. Environ Health. 16:942017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Law AMK, Lim E, Ormandy CJ and
Gallego-Ortega D: The innate and adaptive infiltrating immune
systems as targets for breast cancer immunotherapy. Endocr Relat
Cancer. 24:X12017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li Y, Li S, Meng X, Gan RY, Zhang JJ and
Li HB: Dietary natural products for prevention and treatment of
breast cancer. Nutrients. 9(pii): E7282017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Boix-Perales H, Borregaard J, Jensen KB,
Ersbøll J, Galluzzo S, Giuliani R, Ciceroni C, Melchiorri D,
Salmonson T, Bergh J, et al: The European medicines agency review
of pertuzumab for the treatment of adult patients with
HER2-positive metastatic or locally recurrent unresectable breast
cancer: Summary of the scientific assessment of the committee for
medicinal products for human use. Oncologist. 19:766–773. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Folkman J: Angiogenesis: An organizing
principle for drug discovery. Nat Rev Drug Discov. 6:273–286. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carmeliet P: Angiogenesis in health and
disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ching YP, Wong CM, Chan SF, Leung TH, Ng
DC, Jin DY and Ng IO: Deleted in liver cancer (DLC) 2 encodes a
RhoGAP protein with growth suppressor function and is
underexpressed in hepatocellular carcinoma. J Biol Chem.
278:10824–10830. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vitiello E, Ferreira JG, Maiato H, Balda
MS and Matter K: The tumour suppressor DLC2 ensures mitotic
fidelity by coordinating spindle positioning and cell-cell
adhesion. Nat Commun. 5:58262014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan FK, Chung SS, Ng IO and Chung SK: The
RhoA GTPase-activating protein DLC2 modulates RhoA activity and
hyperalgesia to noxious thermal and inflammatory stimuli.
Neurosignals. 20:112–126. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ullmannova V and Popescu NC: Expression
profile of the tumor suppressor genes DLC-1 and DLC-2 in solid
tumors. Int J Oncol. 29:1127–1132. 2006.PubMed/NCBI
|
|
11
|
Lin Y, Chen NT, Shih YP, Liao YC, Xue L
and Lo SH: DLC2 modulates angiogenic responses in vascular
endothelial cells by regulating cell attachment and migration.
Oncogene. 29:3010–3016. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yakirevich E, Magi-Galluzzi C, Grada Z, Lu
S, Resnick MB and Mangray S: Cadherin 17 is a sensitive and
specific marker for metanephric adenoma. Am J Surg Pathol.
39:479–486. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lakhani SR, Ellis IO, Schnitt SJ, Tan PH
and van de Vijver MJ: WHO classification of tumours of the breast.
Fourth edition. Int Agency Res Cancer. 9–27. 2016.
|
|
14
|
Hanna S, Khalil B, Nasrallah A, Saykali
BA, Sobh R, Nasser S and El-Sibai M: StarD13 is a tumor suppressor
in breast cancer that regulates cell motility and invasion. Int J
Oncol. 44:1499–1511. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
El-Sitt S, Khalil BD, Hanna S, El-Sabban
M, Fakhreddine N and El-Sibai M: DLC2/StarD13 plays a role of a
tumor suppressor in astrocytoma. Oncol Rep. 28:511–518. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Leung TH, Yam JW, Chan LK, Ching YP and Ng
IO: Deleted in liver cancer 2 suppresses cell growth via the
regulation of the Raf-1-ERK1/2-p70S6K signalling pathway. Liver
Int. 30:1315–1323. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leung TH, Ching YP, Yam JW, Wong CM, Yau
TO, Jin DY and Ng IO: Deleted in liver cancer 2 (DLC2) suppresses
cell transformation by means of inhibition of RhoA activity. Proc
Natl Acad Sci USA. 102:15207–15212. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yuan BZ, Zhou X, Durkin ME, Zimonjic DB,
Gumundsdottir K, Eyfjord JE, Thorgeirsson SS and Popescu NC: DLC-1
gene inhibits human breast cancer cell growth and in vivo
tumorigenicity. Oncogene. 22:445–450. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yuan BZ, Jefferson AM, Baldwin KT,
Thorgeirsson SS, Popescu NC and Reynolds SH: DLC-1 operates as a
tumor suppressor gene in human non-small cell lung carcinomas.
Oncogene. 23:1405–1411. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Thorgeirsson SS and Popescu NC:
Restoration of DLC-1 gene expression induces apoptosis and inhibits
both cell growth and tumorigenicity in human hepatocellular
carcinoma cells. Oncogene. 23:1308–1313. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lukasik D, Wilczek E, Wasiutynski A and
Gornicka B: Deleted in liver cancer protein family in human
malignancies (Review). Oncol Lett. 2:763–768. 2011.PubMed/NCBI
|
|
22
|
Kawai K, Kiyota M, Seike J, Deki Y and
Yagisawa H: START-GAP3/DLC3 is a GAP for RhoA and Cdc42 and is
localized in focal adhesions regulating cell morphology. Biochem
Biophys Res Commun. 364:783–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zheng L, Li X, Chou J, Xiang C, Guo Q,
Zhang Z, Guo X, Gao L, Xing Y and Xi T: StarD13 3′-untranslated
region functions as a ceRNA for TP53INP1 in prohibiting migration
and invasion of breast cancer cells by regulating miR-125b
activity. Eur J Cell Biol. 97:23–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shih YP, Liao YC, Lin Y and Lo SH: DLC1
negatively regulates angiogenesis in a paracrine fashion. Cancer
Res. 70:8270–8275. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tcherkezian J and Lamarche-Vane N: Current
knowledge of the large RhoGAP family of proteins. Biol Cell.
99:67–86. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petzold KM, Naumann H and Spagnoli FM: Rho
signalling restriction by the RhoGAP Stard13 integrates growth and
morphogenesis in the pancreas. Development. 140:126–135. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Khalil BD, Hanna S, Saykali BA, El-Sitt S,
Nasrallah A, Marston D, El-Sabban M, Hahn KM, Symons M and El-Sibai
M: The regulation of RhoA at focal adhesions by StarD13 is
important for astrocytoma cell motility. Exp Cell Res. 321:109–122.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang F, Zhang R, He Y, Zou M, Guo L and Xi
T: MicroRNA-125b induces metastasis by targeting STARD13 in MCF-7
and MDA-MB-231 breast cancer cells. PLoS One. 7:e354352012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li X, Zheng L, Zhang F, Hu J, Chou J, Liu
Y, Xing Y and Xi T: STARD13-correlated ceRNA network inhibits EMT
and metastasis of breast cancer. Oncotarget. 7:23197–23211.
2016.PubMed/NCBI
|
|
30
|
Hu J, Li X, Guo X, Guo Q, Xiang C, Zhang
Z, Xing Y, Xi T and Zheng L: The CCR2 3′UTR functions as a
competing endogenous RNA to inhibit breast cancer metastasis. J
Cell Sci. 130:3399–3413. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guo X, Xiang C, Zhang Z, Zhang F, Xi T and
Zheng L: Displacement of Bax by BMF Mediates STARD13 3′UTR-induced
breast cancer cells apoptosis in an miRNA-depedent manner. Mol
Pharm. 15:63–71. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American Society of
Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
